Dasatinib
Dasatinib is a second-generation, orally bioavailable tyrosine kinase inhibitor (TKI) developed primarily for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Dasatinib is a second-generation, orally bioavailable tyrosine kinase inhibitor (TKI) developed primarily for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It exerts its anticancer effects by potently inhibiting BCR-ABL1, the constitutively active fusion kinase that drives CML pathogenesis, as well as a broad spectrum of additional kinases including SRC-family kinases, c-Kit, PDGFR, and ephrin receptors. This multitarget profile distinguishes dasatinib from first-generation TKIs such as imatinib and underpins both its enhanced potency against BCR-ABL1 mutations and its broader applicability across multiple tumor types. Dasatinib binds BCR-ABL1 primarily in its active conformation, giving it activity against many imatinib-resistant mutants. Its inhibition of SRC-family kinases is particularly relevant beyond CML, as SRC-mediated compensatory signaling is a recognized resistance mechanism in non-small cell lung cancer and other solid tumors.
Despite its clinical efficacy, dasatinib carries a well-characterized toxicity profile that includes pleural effusions, pulmonary arterial hypertension, and cardiopulmonary complications. Dose optimization has therefore become a central research question in CML management, aiming to preserve therapeutic depth of response while mitigating adverse effects and reducing treatment cost. Emerging evidence also positions dasatinib as a candidate agent in several solid tumor contexts, including triple-negative breast cancer (TNBC) and pediatric diffuse intrinsic pontine glioma (DIPG), reflecting the broad oncological relevance of its kinase inhibition profile.
Where the papers sit
14 papers from the last 6 months study dasatinib directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 5 observational · 9 preclinical
Themes 3 themes · 1 new direction
-
Cellular Senescence and Inflammation
Cellular senescence is being linked to inflammation, impaired stem-cell function, metabolic dysfunction and tissue degeneration. Dasatinib-related interventions target senescent T cells or adipocytes, with MAPK14/NF-κB and uPAR pathways recurring. Other work connects senescence with sickle-cell disease, muscle atrophy and posttraumatic osteoarthritis. The field remains mechanistically broad, with senescence reduction pursued as a way to restore tissue and immune function.
6 papers · 42.9%
-
Chronic Myeloid Leukemia Outcomes
Chronic myeloid leukemia care is moving toward longitudinal molecular response monitoring alongside treatment safety surveillance. BCR-ABL1 transcript decline velocity and international-scale measurements are used to interpret TKI response and switching. Cardiovascular assessment recurs through echocardiography and arterial-stiffness testing, while proton pump inhibitor use may influence dasatinib treatment changes. Rare complications such as cervicofacial oedema remain part of ongoing risk characterization.
5 papers · 35.7%
-
Localized Antitumor Immunotherapy
pH-sensitive hydrogels and albumin nanoparticles are being used to localize dasatinib at residual tumors. Melanoma studies emphasize local eradication while limiting systemic exposure. Timed dasatinib priming can reduce MHC class I inhibition of NK and anti-CD19 CAR-NK cells. The work is moving toward combining targeted delivery with improved innate immune cytotoxicity.
3 papers · 21.4%
Dasatinib emerges as a reversible regulator of lymph-node perfusion and lymphocyte trafficking
The paper on peripheral lymph nodes begins with the unresolved question of how dasatinib affects lymphocyte surveillance beyond the spleen. Instead of merely serving as a leukemia treatment or immune-cell modulator, dasatinib caused transient inhibition of T- and B-cell motility by inducing vasoconstriction, lymph-node hypoxia, and reduced interstitial movement in vivo; ROCK inhibition reversed the hypoxia and rescued CD8+ T-cell motility 42555708Aug. This identifies dasatinib as a reversible regulator of lymph-node vascular physiology and immune-cell trafficking, opening a direction distinct from the therapeutic, senolytic, and ex vivo cell-engineering roles represented elsewhere in the set.
Papers
The 14 papers from the last 6 months that study dasatinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Cellular Senescence and Inflammation (6)
- Dasatinib alleviates inflammation in sepsis by inhibiting T cell senescence via MAPK14 /NF-κB axis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 17 Aug 2026 PMID 42607350
- Dasatinib reversibly disrupts T cell motility and activation in lymph nodes. Science advances · 5 Aug 2026 PMID 42555708
- Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans. Science translational medicine · 22 Jul 2026 PMID 42485438
- Enhancing insulin sensitivity by reducing adipocyte senescence using uPAR-targeted nanoparticles in high-fat-diet-induced obese mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442548
- Integrative multi-omics and machine learning reveal PLAUR as a Pan-Cancer prognostic biomarker and potential therapeutic target. Bioorganic chemistry · 2 Jul 2026 PMID 42391812
- Cellular senescence links muscle atrophy and posttraumatic osteoarthritis after ACL injury. Function (Oxford, England) · 25 Jun 2026 PMID 42348390
Chronic Myeloid Leukemia Outcomes (5)
- Dasatinib-induced cervicofacial oedema in chronic myeloid leukaemia blast crisis. BMJ case reports · 19 Aug 2026 PMID 42618311
- Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
- Association between proton pump inhibitor co-medication and treatment switching in dasatinib-treated patients with chronic myeloid leukemia: a German real-world evidence study. Annals of hematology · 30 Jul 2026 PMID 42530652
- Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study. Cancer · 15 Jul 2026 PMID 42455913
- A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib. Echocardiography (Mount Kisco, N.Y.) · 28 May 2026 PMID 42206579
Localized Antitumor Immunotherapy (3)
- Timing-dependent dasatinib priming attenuates MHC class I-mediated inhibition of NK cells and CAR-NK cells. Oncoimmunology · 14 Nov 2026 PMID 43033140
- Construction of pH-Sensitive Dynamic Composite Hydrogels and Their Local Targeted Antitumor Research. ACS applied bio materials · 27 Oct 2026 PMID 42945386
- Dasatinib-Loaded Human Serum Albumin Nanoparticle-Impregnated Hydrogel for Localised Eradication of Residual Melanoma: Integrated In Silico, 3D Spheroid, and Dermatokinetic Evaluation. ACS applied bio materials · 17 Aug 2026 PMID 42606056
By study type
Observational studies and case reports (5)
- Dasatinib-induced cervicofacial oedema in chronic myeloid leukaemia blast crisis. BMJ case reports · 19 Aug 2026 PMID 42618311
- Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
- Association between proton pump inhibitor co-medication and treatment switching in dasatinib-treated patients with chronic myeloid leukemia: a German real-world evidence study. Annals of hematology · 30 Jul 2026 PMID 42530652
- Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study. Cancer · 15 Jul 2026 PMID 42455913
- A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib. Echocardiography (Mount Kisco, N.Y.) · 28 May 2026 PMID 42206579
Preclinical: animal, cell and lab studies (9)
- Timing-dependent dasatinib priming attenuates MHC class I-mediated inhibition of NK cells and CAR-NK cells. Oncoimmunology · 14 Nov 2026 PMID 43033140
- Construction of pH-Sensitive Dynamic Composite Hydrogels and Their Local Targeted Antitumor Research. ACS applied bio materials · 27 Oct 2026 PMID 42945386
- Dasatinib alleviates inflammation in sepsis by inhibiting T cell senescence via MAPK14 /NF-κB axis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 17 Aug 2026 PMID 42607350
- Dasatinib-Loaded Human Serum Albumin Nanoparticle-Impregnated Hydrogel for Localised Eradication of Residual Melanoma: Integrated In Silico, 3D Spheroid, and Dermatokinetic Evaluation. ACS applied bio materials · 17 Aug 2026 PMID 42606056
- Dasatinib reversibly disrupts T cell motility and activation in lymph nodes. Science advances · 5 Aug 2026 PMID 42555708
- Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans. Science translational medicine · 22 Jul 2026 PMID 42485438
- Enhancing insulin sensitivity by reducing adipocyte senescence using uPAR-targeted nanoparticles in high-fat-diet-induced obese mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442548
- Integrative multi-omics and machine learning reveal PLAUR as a Pan-Cancer prognostic biomarker and potential therapeutic target. Bioorganic chemistry · 2 Jul 2026 PMID 42391812
- Cellular senescence links muscle atrophy and posttraumatic osteoarthritis after ACL injury. Function (Oxford, England) · 25 Jun 2026 PMID 42348390
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-08-26 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.